Payment overview · 2025
General Payments
$366.67
4 reported records · 4 companies
Healthcare provider profile · identity verified
Cara E. Stansifer, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FORT WAYNE, IN · NPI 1518273887
Verified facts
What the public records show
CMS Open Payments records show Cara E. Stansifer, NP received $366.67 in general payments during 2025 across 4 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $123.86 | 33.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $116.48 | 31.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $107.93 | 29.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.40 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $366.67 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $123.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $116.48 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $107.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 95 |
| Gabapentin | Gabapentin | 491 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 43 |
| Omeprazole | Omeprazole | 287 | 40 |
| Trazodone Hcl | Trazodone Hcl | 281 | 33 |
| Furosemide | Furosemide | 278 | 45 |
| Eliquis | Apixaban | 273 | 30 |
| Metformin Hcl | Metformin Hcl | 264 | 34 |
| Potassium Chloride | Potassium Chloride | 246 | 30 |
| Lisinopril | Lisinopril | 240 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 28 |
| Carvedilol | Carvedilol | 205 | 29 |
| Losartan Potassium | Losartan Potassium | 204 | 28 |
| Sertraline Hcl | Sertraline Hcl | 198 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 27 |
| Tramadol Hcl | Tramadol Hcl | 150 | 23 |
| Buspirone Hcl | Buspirone Hcl | 139 | 17 |
| Famotidine | Famotidine | 136 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 16 |
| Donepezil Hcl | Donepezil Hcl | 132 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 38 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 121 | 38 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 117 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 15 |
| Jardiance | Empagliflozin | 100 | 12 |
| Risperidone | Risperidone | 98 | suppressed |
| Baclofen | Baclofen | 96 | 19 |
| Levetiracetam | Levetiracetam | 95 | 12 |
| Spironolactone | Spironolactone | 94 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | suppressed |
| Meloxicam | Meloxicam | 86 | 15 |
| Mirtazapine | Mirtazapine | 79 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 11 |
| Metformin Hcl Er | Metformin Hcl | 74 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 74 | suppressed |
| Latanoprost | Latanoprost | 73 | 11 |
| Pregabalin | Pregabalin | 70 | 14 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Bumetanide | Bumetanide | 68 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 17 |
| Ozempic | Semaglutide | 65 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 63 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Topiramate | Topiramate | 58 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Olanzapine | Olanzapine | 55 | suppressed |
| Nystatin | Nystatin | 54 | 19 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Tradjenta | Linagliptin | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 21 |
| Invega Sustenna | Paliperidone Palmitate | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 38 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 48 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Hydrocortisone | Hydrocortisone | 47 | 19 |
| Lacosamide | Lacosamide | 47 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Torsemide | Torsemide | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 12 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Prednisone | Prednisone | 37 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 36 | 16 |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 18 |
| Digoxin | Digoxin | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 23 |
| Gemtesa | Vibegron | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 19 |
| Fluconazole | Fluconazole | 25 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $366.67 · 4 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, INGREZZA, REXULTI, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error